EGFR and neoplasm: Several preclinical studies have examined the anti-tumour activity of inhibitors of EGFR and anti-angiogenic agents in combination and have demonstrated at least additive, if not synergistic, effects (Ciardiello et al, 2000; Jung et al, 2002; Herbst et al, 2003).